Figure 2
Figure 2. Molecular responses. (A) Cumulative incidence of MR4.5 in patients without MR4.5 at study start. (B) Cumulative incidence of confirmed MR4.5 among patients without MR4.5 at study start. (C) Cumulative incidence of undetectable BCR-ABL1 in patients with detectable BCR-ABL1 at study start. (D) Cumulative incidence of confirmed undetectable BCR-ABL1 among patients with detectable BCR-ABL1 at study start. (E) Molecular responses in patients without MMR at study start.

Molecular responses. (A) Cumulative incidence of MR4.5 in patients without MR4.5 at study start. (B) Cumulative incidence of confirmed MR4.5 among patients without MR4.5 at study start. (C) Cumulative incidence of undetectable BCR-ABL1 in patients with detectable BCR-ABL1 at study start. (D) Cumulative incidence of confirmed undetectable BCR-ABL1 among patients with detectable BCR-ABL1 at study start. (E) Molecular responses in patients without MMR at study start.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal